CVE:RX BioSyent (RX) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free RX Stock Alerts C$8.51 +0.11 (+1.31%) (As of 04/25/2024 05:18 PM ET) Add Compare Share Share Today's RangeC$8.50▼C$8.5150-Day RangeC$8.40▼C$8.7852-Week RangeC$7.03▼C$9.26Volume7,093 shsAverage Volume5,957 shsMarket CapitalizationC$98.80 millionP/E Ratio16.06Dividend Yield2.12%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades Get BioSyent alerts: Email Address Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024 About BioSyent Stock (CVE:RX)BioSyent Inc., through its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It also offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Read More RX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RX Stock News HeadlinesApril 16, 2024 | finanznachrichten.deBioSyent Inc.: BioSyent Announces Extension of RepaGyn and Proktis-M AgreementApril 4, 2024 | finance.yahoo.comBioSyent Inc.'s (CVE:RX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.April 3, 2024 | markets.businessinsider.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive YearMarch 21, 2024 | finanznachrichten.deBioSyent Inc.: BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023March 16, 2024 | uk.investing.comEarnings call: BioSyent Inc. reports robust growth in Q4 and FY 2023February 21, 2024 | markets.businessinsider.comBioSyent Named to 2024 TSX Venture 50February 17, 2024 | seekingalpha.comRX:CA BioSyent Inc.April 26, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.February 6, 2024 | markets.businessinsider.comBioSyent Declares First Quarter 2024 DividendNovember 24, 2023 | finance.yahoo.comIs It Smart To Buy BioSyent Inc. (CVE:RX) Before It Goes Ex-Dividend?November 20, 2023 | finance.yahoo.comBioSyent Announces the Availability of Gelclair® in CanadaNovember 20, 2023 | markets.businessinsider.comBloom Burton Believes Biosyent (RX) Won’t Stop HereNovember 16, 2023 | finance.yahoo.comBioSyent Releases Q3 and YTD 2023 Financial ResultsNovember 15, 2023 | markets.businessinsider.comBioSyent Declares Fourth Quarter 2023 DividendOctober 23, 2023 | es-us.finanzas.yahoo.comInvestors in BioSyent (CVE:RX) have seen returns of 21% over the past yearOctober 18, 2023 | theglobeandmail.comClosing Bell: Biosyent Inc flat on Tuesday (RX)October 18, 2023 | theglobeandmail.comBioSyent Launches "menopauseinformation.ca" on World Menopause DayAugust 31, 2023 | theglobeandmail.comClosing Bell: Biosyent Inc flat on Wednesday (RX)August 26, 2023 | finance.yahoo.comWhy You Might Be Interested In BioSyent Inc. (CVE:RX) For Its Upcoming DividendAugust 24, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of BioSyent Inc. (CVE:RX)August 23, 2023 | finanznachrichten.deBioSyent Inc.: BioSyent Releases Q2 and H1 2023 Financial ResultsAugust 22, 2023 | markets.businessinsider.comBioSyent Declares Third Quarter 2023 DividendAugust 8, 2023 | finance.yahoo.comBioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)July 18, 2023 | theglobeandmail.comClosing Bell: Biosyent Inc down on Monday (RX)July 6, 2023 | finance.yahoo.comBioSyent Pharma to Introduce Gelclair® at AHNS 11th International Conference on Head and Neck CancerJune 20, 2023 | finance.yahoo.comBioSyent Announces Long-term Extension of Cathejell® AgreementSee More Headlines Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/26/2024Next Earnings (Estimated)5/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:RX CUSIPN/A CIKN/A Webwww.biosyent.com Phone+1-905-2060013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.53 Trailing P/E Ratio16.06 Forward P/E Ratio18.18 P/E GrowthN/ANet IncomeC$6.46 million Net Margins20.45% Pretax MarginN/A Return on Equity18.97% Return on Assets11.39% Debt Debt-to-Equity Ratio3.51 Current Ratio6.48 Quick Ratio6.91 Sales & Book Value Annual SalesC$31.59 million Price / Sales3.13 Cash FlowC$2.77 per share Price / Cash Flow3.07 Book ValueC$2.96 per share Price / Book2.88Miscellaneous Outstanding Shares11,610,000Free FloatN/AMarket CapC$98.80 million OptionableNot Optionable Beta0.93 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. René C. Goehrum (Age 65)Chairman, CEO & President Comp: $534.76kMr. Robert J. MarchVP of Finance & CFOMr. Joost van der MarkVice President of Corporate DevelopmentMs. Neelu AtwalDirector of Human ResourcesMr. Alfred D'SouzaAdvisorKey CompetitorsGreen Organic DutchmanTSE:TGODDelta 9 CannabisCVE:NINEWeedMDCVE:WMDDecibel CannabisCVE:DBCharlotte's WebTSE:CWEBView All CompetitorsInsidersLarry AndrewsBought 1,000 shares on 3/28/2024Total: C$8,700.00 ($8.70/share)Peter Douglas LockhardSold 600 sharesTotal: C$5,220.00 ($8.70/share)Seyed Ahmad AshrafiSold 1,000 sharesTotal: C$8,500.00 ($8.50/share)View All Insider Transactions RX Stock Analysis - Frequently Asked Questions How have RX shares performed in 2024? BioSyent's stock was trading at C$9.22 at the start of the year. Since then, RX shares have decreased by 7.7% and is now trading at C$8.51. View the best growth stocks for 2024 here. When is BioSyent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 24th 2024. View our RX earnings forecast. How were BioSyent's earnings last quarter? BioSyent Inc. (CVE:RX) announced its quarterly earnings results on Wednesday, March, 13th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.17 by $0.05. The firm earned $8.27 million during the quarter, compared to analyst estimates of $8.80 million. BioSyent had a net margin of 20.45% and a trailing twelve-month return on equity of 18.97%. Is BioSyent a good dividend stock? BioSyent (CVE:RX) pays an annual dividend of C$0.18 per share and currently has a dividend yield of 2.07%. The dividend payout ratio is 33.96%. This payout ratio is at a healthy, sustainable level, below 75%. What other stocks do shareholders of BioSyent own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioSyent investors own include Aurora Cannabis (ACB), Canadian National Railway (CNR), Bank of Nova Scotia (BNS), Cross Timbers Royalty Trust (CRT), Dollarama (DOL), Enbridge (ENB), Gilead Sciences (GILD), National Bank of Canada (NA) and Air Canada (AC). How do I buy shares of BioSyent? Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (CVE:RX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.